Market Place
Sourcing Support
Transcode Therapeutics Secures $20M Financing, Extending Runway
07 Apr 2026 //
PR NEWSWIRE
TransCode Publishes RIG-I Preclinical Data
23 Feb 2026 //
PR NEWSWIRE
Transcode Therapeutics, Quantum Leap Submit IND Amendment
05 Feb 2026 //
PR NEWSWIRE
TransCode Therapeutics Publishes TTX-MC138 Cancer Data
06 Jan 2026 //
PR NEWSWIRE
Transcode Therapeutics Appoints Jack E. Stover To Board
22 Dec 2025 //
PR NEWSWIRE BIO
Transcode Therapeutics Unveils Phase 1a Results with TTX-MC138
14 Oct 2025 //
PR NEWSWIRE
Transcode Rewrites Future, Securing $25M And Phase 3 Vaccine
08 Oct 2025 //
FIERCE BIOTECH
TransCode Completes Dosing in Phase 1a Trial Cohort 4
08 May 2025 //
PR NEWSWIRE
TransCode Reports Progress on Phase 1a Trial in Metastatic Cancer
01 May 2025 //
PR NEWSWIRE
TransCode Gets Approval to Open Fourth Cohort in Ph I/II Clinical Trial
13 Mar 2025 //
PR NEWSWIRE
TransCode Completes Cohort 3 Initial Dosing in Phase 1 Trial
06 Feb 2025 //
PR NEWSWIRE
TransCode Doses Third Cohort in Phase 1 Trial With Lead Candidate
14 Jan 2025 //
PR NEWSWIRE
TransCode Announces Effective Date For 1-for-33 Reverse Stock Split
29 Nov 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces $8 Million Private Placement
27 Nov 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
25 Nov 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Phase 1 Trial Cohort 2 Approved
23 Oct 2024 //
GLOBENEWSWIRE
TransCode Complete Dosing 1st Cohort in Ph 1, microRNA Technology
10 Oct 2024 //
GLOBENEWSWIRE
TransCode Announces Treats First Patients in Phase 1 Trial
17 Sep 2024 //
GLOBENEWSWIRE
TransCode Publishes Study On Lead Cancer Therapeutic
10 Sep 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Awarded $2 Million NIH Grant
05 Sep 2024 //
GLOBENEWSWIRE
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 Aug 2024 //
GLOBENEWSWIRE
TransCode Reports Positive First-In-Human Data For TTX-MC138
29 May 2024 //
GLOBENEWSWIRE
TransCode Gets FDA Clearance For TTX-MC138 Phase 1/2
15 Apr 2024 //
GLOBENEWSWIRE
TransCode and Akribion Report Progress Developing CRISPR-Derived Technology
11 Mar 2024 //
GLOBENEWSWIRE
TransCode Reports PositiveResults in Metastatic Pancreatic Cancer with TTX-MC138
12 Dec 2023 //
GLOBENEWSWIRE
TransCode Announces Prolonged Survival in Murine Models with Glioblastoma
26 Oct 2023 //
GLOBENEWSWIRE
TransCode Announces Positive Pre-Clinical Glioblastoma Results with TTX-MC138
25 Sep 2023 //
GLOBENEWSWIRE
TransCode Announces First Subject Dosed with TTX-MC138 in First-In-Human Trial
23 Aug 2023 //
GLOBENEWSWIRE
TransCode Announces Positive Results in Non-human Primates with TTX-MC138
31 Jul 2023 //
GLOBENEWSWIRE
TransCode Announces Publication of New Data Supporting the Use of TTX-MC138
22 Jun 2023 //
GLOBENEWSWIRE
TransCode Reports Positive Results with its Lead Candidate, TTX-MC138
06 Jun 2023 //
GLOBENEWSWIRE
TransCode Announces Equity Investment from White Lion Capital
14 Apr 2023 //
GLOBENEWSWIRE
TransCode Therapeutics Receives Notice of Award from NIH for TTX-MC138
05 Apr 2023 //
GLOBENEWSWIRE
TransCode and BRAIN join forces to develop a CRISPR-derived technology platform
22 Feb 2023 //
GLOBENEWSWIRE
TransCode Reports Positive Results with its Immunotherapy Candidate, TTX-RIGA
31 Jan 2023 //
GLOBENEWSWIRE
